Shilpa Medicare, established in 1987, has carved a niche for itself in the exceedingly competitive and quality-conscious sphere of pharmaceuticals manufacturing. It produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.  

The company has earned its spurs as a successful and reliable partner within the pharmaceutical industry. Buyers within the country and from across the borders count on its fast track integrated process development and finely honed expertise of its skilled and experienced personnel. The company is already exporting to USA, Canada, Australia, Japan and European countries viz., Germany, Switzerland, Netherlands, Belgium, Spain, Greece, Cyprus, Italy, United Kingdom etc., South American countries like Mexico, Brazil, Columbia etc, African countries like Kenya, Nigeria and West Indies etc, Asian countries like Singapore, Taiwan, China, Malaysia, Thailand and closer to home to Iran, Egypt, Pakistan and Bangladesh.  Shilpa Medicare is synergizing strength through tie-ups for manufacturing products and co-marketing rights, for it believes in working together and sharing success.

Being proactive in approach, the company continually seeks out enquiry’s for development of new products drawing from the extensive knowledge-base of its qualified and experienced people as well as sophisticated facilities.

Product range of the company includes:

Shilpa Medicare Ltd.

Unichem Laboratories Ltd.

Marksans Pharma Ltd.

Sequent Scientific Ltd.

Neuland Laboratories Ltd.

Strides Pharma Science Ltd.

Advanced Enzyme Technologies Ltd.

Amrutanjan Health Care Ltd.

Gufic Biosciences Ltd.

IOL Chemicals And Pharmaceuticals Ltd.

Supriya Lifescience Ltd.

Alembic Ltd.

Wockhardt Ltd.

AMI Organics Ltd.

Indoco Remedies Ltd.

HDFC Bank Ltd.

ICICI Bank Ltd.

ITC Ltd.

Reliance Industries Ltd.

Tata Motors Ltd.

Market Cap	2,644 Cr		EPS	2.1		High	304.7
Stock P/E	146.5		Net Profit Margin	-6.2		Low	300

Market Cap	2,644 Cr	ROE	3.7%
P/E Ratio(TTM)	146.5	EPS(TTM)	6.9
P/B Ratio	1.2	Dividend Yield	0.4%
Industry P/E	63.6	Book Value	247.5
		Face Value	1.0

SHILPAMED